Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
SAN DIEGO, April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET. The event will include presentations from members of the Company's leadership team highlighting the renewed focus across the Acute Care and Oncology franchises and panel discussions featuring patient and physician experience with Heron's commercial products. The presentations will also include updates on several ongoing initiatives in the Acute Care franchise to expand reach and adoption.
聖地亞哥，2024年4月11日 /PRNewswire/ — 處於商業階段的生物技術公司Heron Therapeutics, Inc.（納斯達克股票代碼：HRTX）今天宣佈，將於美國東部時間2024年5月15日星期三上午9點30分開始在紐約市舉辦投資者日。該活動將包括公司領導團隊成員的演講，重點介紹急性護理和腫瘤學系列的新焦點，以及介紹患者和醫生使用Heron商業產品的經驗的小組討論。演講還將包括Acute Care系列中爲擴大覆蓋面和採用率而正在進行的幾項舉措的最新情況。
The event will include a live webcast which will be archived and available for replay after the event. Please visit the "Investors" section of the Company website at Investor Resources - Heron Therapeutics (herontx.com) to register for the webcast and for additional information on the event.
該活動將包括網絡直播，該直播將在活動結束後存檔並可供重播。請訪問公司網站投資者資源——Heron Therapeutics（herontx.com）的 “投資者” 欄目，註冊觀看網絡直播並了解有關該活動的更多信息。
About Heron Therapeutics, Inc.
關於 Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit .
Heron Therapeutics, Inc. 是一家處於商業階段的生物技術公司，專注於通過開發和商業化改善醫療保健的治療創新來改善患者的生活。我們先進的科學、專利技術和創新的藥物發現和開發方法使我們能夠創建和商業化一系列旨在提高急性護理和腫瘤患者的護理標準的產品組合。欲了解更多信息，請訪問。
Forward-looking Statements
前瞻性陳述
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
本新聞稿包含1995年《私人證券訴訟改革法》所定義的 “前瞻性陳述”。Heron提醒讀者，前瞻性陳述基於管理層截至本新聞稿發佈之日的預期和假設，存在某些風險和不確定性，可能導致實際業績存在重大差異。這些風險和不確定性包括但不限於公司向美國證券交易委員會提交的文件中確定的風險和不確定性。前瞻性陳述僅在規定的日期反映我們的分析，除非法律要求，否則Heron沒有義務更新或修改這些陳述。
Investor Relations and Media Contact:
投資者關係和媒體聯繫人：
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
艾拉·杜阿爾特
執行副總裁、首席財務官
Heron Therapeutics, Inc
[電子郵件保護]
858-251-4400
SOURCE Heron Therapeutics, Inc.
來源 Heron Therapeutics, Inc.